Einzeltreffer — DigiBib

The Eya family of proteins (consisting of Eyas1-4 in mammals) play vital roles in embryogenesis by regulating processes such as proliferation, migration/invasion, cellular survival and pluripotency/plasticity of epithelial and mesenchymal states. Eya proteins carry out such diverse functions through a unique combination of transcriptional co-factor, Tyr phosphatase, and PP2A/B55α-mediated Ser/Thr phosphatase activities. Since their initial discovery, re-expression of Eyas has been observed in numerous tumor types, where they are known to promote tumor progression through a combination of their transcriptional and enzymatic activities. Eya proteins thus reinstate developmental processes during malignancy and represent a compelling class of therapeutic targets for inhibiting tumor progression.

Competing Interests: Declaration of competing interest Heide Ford reports financial support was provided by National Institutes of Health. Rui Zhao reports financial support was provided by Cancer League of Colorado. Rui Zhao reports financial support was provided by National Institutes of Health. Connor Hughes reports financial support was provided by National Institutes of Health. Chris Alderman reports financial support was provided by National Institutes of Health. Heide Ford and Rui Zhao has patent #63/582,521 EYA2 INHIBITORS AND METHODS FOR USING AND PRODUCING THE SAME pending to n/a. None If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Titel:	All eyes on Eya: A unique transcriptional co-activator and phosphatase in cancer.
Autor/in / Beteiligte Person:	Hughes, CJ ; Alderman, C ; Wolin, AR ; Fields, KM ; Zhao, R ; Ford, HL
Zeitschrift:	Biochimica et biophysica acta. Reviews on cancer, Jg. 1879 (2024-05-01), Heft 3, S. 189098
Veröffentlichung:	Amsterdam : Elsevier, 2024
Medientyp:	academicJournal
ISSN:	1879-2561 (electronic)
DOI:	10.1016/j.bbcan.2024.189098
Schlagwort:	Humans Animals Gene Expression Regulation, Neoplastic Intracellular Signaling Peptides and Proteins metabolism Intracellular Signaling Peptides and Proteins genetics Eye Proteins metabolism Eye Proteins genetics Nuclear Proteins metabolism Nuclear Proteins genetics Neoplasms genetics Neoplasms pathology Neoplasms metabolism Protein Tyrosine Phosphatases metabolism Protein Tyrosine Phosphatases genetics
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Review Language: English [Biochim Biophys Acta Rev Cancer] 2024 May; Vol. 1879 (3), pp. 189098. <i>Date of Electronic Publication: </i>2024 Mar 28. MeSH Terms: Neoplasms* / genetics ; Neoplasms* / pathology ; Neoplasms* / metabolism ; Protein Tyrosine Phosphatases* / metabolism ; Protein Tyrosine Phosphatases* / genetics ; Humans ; Animals ; Gene Expression Regulation, Neoplastic ; Intracellular Signaling Peptides and Proteins / metabolism ; Intracellular Signaling Peptides and Proteins / genetics ; Eye Proteins / metabolism ; Eye Proteins / genetics ; Nuclear Proteins / metabolism ; Nuclear Proteins / genetics References: Oncogene. 2010 Jun 24;29(25):3715-22. (PMID: 20418914) ; Exp Hematol Oncol. 2020 Jun 15;9:13. (PMID: 32550045) ; Mol Cancer Ther. 2021 May;20(5):803-815. (PMID: 33649104) ; FEBS Lett. 2006 Jul 10;580(16):3853-9. (PMID: 16797546) ; Front Oncol. 2021 Oct 21;11:622331. (PMID: 34745930) ; Cell Mol Life Sci. 2013 Jun;70(11):1897-913. (PMID: 22971774) ; Dev Neurosci. 2020;42(5-6):170-186. (PMID: 33472197) ; J Clin Invest. 2004 Aug;114(4):569-81. (PMID: 15314694) ; Breast Cancer Res. 2012 Nov 16;14(6):R148. (PMID: 23158001) ; J Biol Chem. 2002 Feb 1;277(5):3560-7. (PMID: 11700312) ; Int J Mol Sci. 2019 Dec 13;20(24):. (PMID: 31847183) ; Annu Rev Pathol. 2022 Jan 24;17:425-457. (PMID: 34788549) ; Cancer Res. 2010 May 1;70(9):3537-46. (PMID: 20406971) ; Biomed Pharmacother. 2020 Mar;123:109790. (PMID: 31896065) ; Onco Targets Ther. 2017 Feb 21;10:1071-1079. (PMID: 28260921) ; Nat Genet. 2005 Apr;37(4):418-22. (PMID: 15735644) ; Oncogene. 2012 Feb 2;31(5):552-62. (PMID: 21706047) ; Mech Dev. 2001 May;103(1-2):189-92. (PMID: 11335132) ; Development. 2012 Jun;139(11):1965-77. (PMID: 22513373) ; Asian Pac J Cancer Prev. 2022 May 01;23(5):1539-1545. (PMID: 35633536) ; Dev Dyn. 2007 Jun;236(6):1526-34. (PMID: 17477401) ; Int J Biochem Cell Biol. 2018 Mar;96:165-170. (PMID: 28887153) ; Mol Cancer. 2023 Sep 30;22(1):158. (PMID: 37777742) ; J Virol. 2020 Oct 27;94(22):. (PMID: 32878885) ; Annu Rev Biochem. 2007;76:513-38. (PMID: 17341163) ; Nat Immunol. 2002 Nov;3(11):991-8. (PMID: 12407406) ; Am J Transl Res. 2019 Apr 15;11(4):2328-2338. (PMID: 31105839) ; Hum Mol Genet. 2000 Feb 12;9(3):363-6. (PMID: 10655545) ; Cancer Res. 2019 Feb 15;79(4):720-734. (PMID: 30606720) ; PLoS One. 2012;7(4):e34806. (PMID: 22545090) ; Eur J Haematol. 2020 Jul;105(1):3-15. (PMID: 32145037) ; Oncotarget. 2017 Dec 2;8(67):110837-110848. (PMID: 29340020) ; PLoS One. 2013;8(3):e59203. (PMID: 23527134) ; Dev Cell. 2012 Feb 14;22(2):377-90. (PMID: 22340499) ; Int J Clin Exp Pathol. 2014 May 15;7(6):3018-27. (PMID: 25031720) ; Dev Biol. 2005 Aug 15;284(2):323-36. (PMID: 16018995) ; Cytokine Growth Factor Rev. 2001 Mar;12(1):73-90. (PMID: 11312120) ; Clin Exp Rheumatol. 2004 Sep-Oct;22(5):651. (PMID: 15485024) ; PLoS One. 2013 Dec 18;8(12):e84582. (PMID: 24367676) ; Dev Biol. 2006 Oct 15;298(2):430-41. (PMID: 16916509) ; Front Immunol. 2020 Nov 25;11:584626. (PMID: 33324403) ; Genes (Basel). 2017 May 13;8(5):. (PMID: 28505071) ; Adv Cancer Res. 2019;144:55-93. (PMID: 31349904) ; Cell. 1997 Dec 26;91(7):881-91. (PMID: 9428512) ; Mol Cell Biol. 2015 Dec 14;36(5):668-77. (PMID: 26667035) ; Genes Dev. 2002 Oct 15;16(20):2662-71. (PMID: 12381665) ; Expert Opin Ther Targets. 2015 Feb;19(2):213-25. (PMID: 25555392) ; Gene. 2018 Feb 15;643:35-45. (PMID: 29203199) ; Development. 1997 Dec;124(23):4819-26. (PMID: 9428418) ; Nat Commun. 2018 Mar 13;9(1):1047. (PMID: 29535359) ; Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15479-84. (PMID: 20713707) ; Exp Cell Res. 2019 Oct 1;383(1):111495. (PMID: 31301290) ; Am J Med Genet. 1986 Sep;25(1):15-27. (PMID: 3799714) ; Br J Cancer. 2004 Apr 19;90(8):1612-9. (PMID: 15083194) ; Am J Pathol. 2002 Jun;160(6):2181-90. (PMID: 12057921) ; J Biol Chem. 2014 Jun 6;289(23):16349-61. (PMID: 24755226) ; Cancer Metastasis Rev. 2008 Jun;27(2):147-58. (PMID: 18246411) ; Biochem Soc Trans. 2021 Jun 30;49(3):1397-1408. (PMID: 34196366) ; Cell Physiol Biochem. 2018;49(5):1856-1869. (PMID: 30231237) ; Cancer Res. 2023 Aug 1;83(15):2527-2542. (PMID: 37219874) ; Adv Cancer Res. 2019;141:1-42. (PMID: 30691681) ; Sci Transl Med. 2019 Sep 11;11(509):. (PMID: 31511426) ; J Cell Biochem. 2018 Dec;119(12):9997-10004. (PMID: 30145830) ; Adv Biomed Res. 2015 Jul 27;4:139. (PMID: 26322287) ; Cancer Res. 2014 Dec 15;74(24):7357-70. (PMID: 25348955) ; J Cancer. 2022 Jan 1;13(2):527-540. (PMID: 35069900) ; J Clin Invest. 2014 Aug;124(8):3378-90. (PMID: 24960160) ; Protein Sci. 2022 Feb;31(2):422-431. (PMID: 34761455) ; Sci Rep. 2023 May 8;13(1):7442. (PMID: 37156847) ; Mol Cancer Ther. 2018 Aug;17(8):1659-1669. (PMID: 29802120) ; Dev Cell. 2014 Nov 24;31(4):434-47. (PMID: 25458011) ; Nat Genet. 1997 Feb;15(2):157-64. (PMID: 9020840) ; Nat Commun. 2024 Feb 15;15(1):1385. (PMID: 38360978) ; Cancer Res. 2007 Apr 1;67(7):3036-42. (PMID: 17409410) ; Nat Med. 2004 Feb;10(2):175-81. (PMID: 14704789) ; J Exp Med. 2021 Nov 1;218(11):. (PMID: 34617969) ; Elife. 2015 Sep 24;4:. (PMID: 26402456) ; Mol Cell Biol. 2017 Jun 15;37(13):. (PMID: 28416638) ; Front Pharmacol. 2021 Feb 08;11:629266. (PMID: 33628188) ; Nat Struct Mol Biol. 2013 Apr;20(4):447-53. (PMID: 23435380) ; Oncol Lett. 2017 Mar;13(3):1293-1298. (PMID: 28454249) ; Nature. 2003 Nov 20;426(6964):295-8. (PMID: 14628052) ; Oncol Lett. 2017 May;13(5):2891-2896. (PMID: 28521394) ; Mol Oncol. 2018 Jun;12(7):1153-1174. (PMID: 29729076) ; Mol Cell Biol. 2016 Dec 19;37(1):. (PMID: 27795300) ; Mol Cancer Res. 2012 Aug;10(8):1098-108. (PMID: 22723308) ; Nature. 2003 Nov 20;426(6964):299-302. (PMID: 14628053) ; Comb Chem High Throughput Screen. 2023;26(2):330-338. (PMID: 35379118) ; Biochem J. 2001 Feb 1;353(Pt 3):417-39. (PMID: 11171037) ; Mol Cell Biol. 1999 Oct;19(10):6815-24. (PMID: 10490620) ; Neuro Oncol. 2018 Sep 3;20(10):1331-1343. (PMID: 29660031) ; J Clin Invest. 2023 Mar 15;133(6):. (PMID: 36757811) ; J Exp Med. 2005 Nov 21;202(10):1333-9. (PMID: 16301743) ; World J Clin Cases. 2019 Jul 6;7(13):1717-1725. (PMID: 31367632) ; Cancer Manag Res. 2021 Feb 17;13:1581-1589. (PMID: 33628048) ; J Hematol Oncol. 2015 Jun 11;8:67. (PMID: 26063074) ; Nature. 2003 Nov 20;426(6964):247-54. (PMID: 14628042) ; Cancer Res. 2005 Feb 1;65(3):925-32. (PMID: 15705892) ; Oncotarget. 2016 Aug 2;7(31):50755-50765. (PMID: 27203207) ; PLoS One. 2017 Jan 20;12(1):e0169622. (PMID: 28107418) ; Cancer Lett. 1994 Jun 30;81(2):165-9. (PMID: 8012933) ; Technol Cancer Res Treat. 2021 Jan-Dec;20:1533033821992084. (PMID: 33550903) ; J Hematol Oncol. 2016 Nov 8;9(1):119. (PMID: 27821176) ; Mol Cancer Ther. 2019 Sep;18(9):1484-1496. (PMID: 31285279) ; Dev Cell. 2015 Apr 6;33(1):22-35. (PMID: 25816987) ; Cold Spring Harb Perspect Med. 2014 Mar 01;4(3):. (PMID: 24591536) ; FEBS J. 2016 Mar;283(6):1004-24. (PMID: 26507691) ; Nat Genet. 1999 Sep;23(1):113-7. (PMID: 10471511) ; Sci Rep. 2018 Feb 13;8(1):2910. (PMID: 29440662) ; Int J Mol Sci. 2019 May 30;20(11):. (PMID: 31151270) ; Ann Transl Med. 2022 Jul;10(13):752. (PMID: 35957720) ; Mol Cell. 2022 Mar 17;82(6):1123-1139.e8. (PMID: 35182481) ; Cancer Res. 2013 Jul 15;73(14):4488-99. (PMID: 23636126) ; Genes (Basel). 2023 Feb 28;14(3):. (PMID: 36980876) ; BMC Dev Biol. 2008 Dec 22;8:118. (PMID: 19102749) ; J Biol Chem. 2009 Jun 12;284(24):16066-16070. (PMID: 19351884) ; FASEB J. 2010 Feb;24(2):560-9. (PMID: 19858093) ; Hear Res. 2013 Mar;297:13-9. (PMID: 23104013) ; Cancer Res. 2006 Dec 1;66(23):11207-13. (PMID: 17145865) ; ACS Appl Bio Mater. 2023 Jan 16;6(1):164-170. (PMID: 36525564) ; Int J Mol Med. 2017 Nov;40(5):1315-1322. (PMID: 28901379) ; Cell. 2004 Jun 25;117(7):927-39. (PMID: 15210113) ; Genome Biol. 2006;7(7):226. (PMID: 16879729) ; Cell Rep. 2022 Jul 26;40(4):111143. (PMID: 35905720) ; FEBS Lett. 2011 Sep 2;585(17):2714-9. (PMID: 21821028) ; Front Oncol. 2013 May 16;3:120. (PMID: 23720710) ; Proc Natl Acad Sci U S A. 2004 May 25;101(21):8090-5. (PMID: 15141091) ; Nature. 2009 Jul 23;460(7254):520-4. (PMID: 19561593) ; Oncogene. 2007 Feb 1;26(5):711-24. (PMID: 16862183) ; Neuro Oncol. 2023 Dec 8;25(12):2287-2301. (PMID: 37486991) ; Pediatr Nephrol. 2013 Jun;28(6):843-54. (PMID: 22806561) ; FEBS Open Bio. 2018 Aug 01;8(9):1405-1411. (PMID: 30186742) ; Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6478-83. (PMID: 15123840) ; J Biol Chem. 2002 Sep 27;277(39):36671-7. (PMID: 12149248) ; Toxicol Sci. 2012 Apr;126(2):589-99. (PMID: 22223484) ; Cold Spring Harb Perspect Biol. 2012 Oct 01;4(10):. (PMID: 22798543) ; Cancer Sci. 2017 Feb;108(2):216-225. (PMID: 27987372) ; Cell Death Dis. 2020 Mar 30;11(3):210. (PMID: 32231206) ; Nucleic Acids Res. 2010 Nov;38(20):6857-71. (PMID: 20601407) ; Mol Cell Biol. 2006 Apr;26(7):2832-44. (PMID: 16537924) ; Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12608-13. (PMID: 9770533) ; Sci Adv. 2022 Jan 28;8(4):eabl7872. (PMID: 35089787) ; Nat Commun. 2018 Jul 16;9(1):2736. (PMID: 30013081) ; Breast Cancer Res. 2012 Jul 05;14(4):R100. (PMID: 22765220) ; Int J Cancer. 2016 Mar 1;138(5):1067-75. (PMID: 26096807) ; Gynecol Oncol. 2012 May;125(2):451-7. (PMID: 22333994) ; Nature. 2009 Apr 2;458(7238):591-6. (PMID: 19234442) ; Cancer Lett. 2014 Feb 1;343(1):62-73. (PMID: 24051309) ; J Clin Invest. 2018 Jun 1;128(6):2535-2550. (PMID: 29757193) ; Genome Res. 1997 Feb;7(2):128-41. (PMID: 9049631) ; FEBS J. 2013 Jan;280(2):549-71. (PMID: 22607316) ; J Med Chem. 1999 Aug 26;42(17):3199-202. (PMID: 10464006) ; Ann Diagn Pathol. 2021 Dec;55:151815. (PMID: 34534789) ; J Mol Graph Model. 2012 Sep;38:382-8. (PMID: 23085179) ; PLoS One. 2012;7(8):e42725. (PMID: 22916150) ; Int J Urol. 2006 Jun;13(6):761-6. (PMID: 16834657) ; J Biomol Screen. 2013 Jan;18(1):85-96. (PMID: 22820394) ; Am J Med Genet. 1989 Apr;32(4):490-4. (PMID: 2773990) ; Mol Cell Biol. 2003 Sep;23(17):5989-99. (PMID: 12917324) ; Cell Res. 2017 Jan;27(1):96-108. (PMID: 27981969) ; Am J Transl Res. 2021 Apr 15;13(4):2840-2848. (PMID: 34017447) ; Blood. 2011 Jun 23;117(25):6895-905. (PMID: 21518926) Grant Information: R01 NS108396 United States NS NINDS NIH HHS; F30 CA257215 United States CA NCI NIH HHS; R01 CA224867 United States CA NCI NIH HHS; R01 CA221282 United States CA NCI NIH HHS; R01 CA275187 United States CA NCI NIH HHS; T32 CA174648 United States CA NCI NIH HHS; F31 CA275314 United States CA NCI NIH HHS; R35 GM145289 United States GM NIGMS NIH HHS Contributed Indexing: Keywords: Eya proteins; Metastasis; Protein phosphatase 2A; Serine/threonine phosphatase; Transcriptional co-factor; Tyrosine phosphatase Substance Nomenclature: 0 (EYA2 protein, human) ; 0 (EYA1 protein, human) Entry Date(s): Date Created: 20240330 Date Completed: 20240521 Latest Revision: 20240524 Update Code: 20240524 PubMed Central ID: PMC11111358

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

All eyes on Eya: A unique transcriptional co-activator and phosphatase in cancer.